Literature DB >> 22911170

Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus.

Toshihide Shima1, Hirofumi Uto, Kohjiro Ueki, Toshinari Takamura, Yutaka Kohgo, Sumio Kawata, Kohichiroh Yasui, Hyohun Park, Naoto Nakamura, Tatsuaki Nakatou, Nobuyoshi Tanaka, Atsushi Umemura, Masayuki Mizuno, Junko Tanaka, Takeshi Okanoue.   

Abstract

BACKGROUND: The Japan Society of Diabetes Mellitus reported that the leading cause of death in patients with diabetes mellitus (DM) was chronic liver disease; however, there are limited studies investigating the cause of liver injury in these patients. Our study aimed to clarify the clinicopathological features of liver injury and the characteristics of nonalcoholic fatty liver disease (NAFLD) in DM patients.
METHODS: In total, 5,642 DM patients and 365 histologically proven NAFLD patients were enrolled. Clinical and laboratory parameters and liver biopsy results were, respectively, recorded and analyzed for the two sets of patients.
RESULTS: Positivity rates for Hepatitis B surface antigens (HBsAg) and anti-hepatitis C virus antibodies (anti-HCV Ab) were 1.7 and 5.1 %, respectively. The proportion of drinkers consuming 20-59 g and ≥60 g alcohol daily was 14.9 and 4.3 %, respectively. The percentage of DM patients with elevated serum alanine aminotransferase (ALT) levels (≥31 IU/L) was 28.6 %. Alcohol consumption had no significant effect on serum ALT levels. Seventy-two percent of HBsAg-positive patients were serum hepatitis B virus (HBV)-DNA negative, whereas 10 % exhibited high levels of the same (>4.0 log copies/ml). Thirty-eight percent of anti-HCV Ab-positive patients were serum HCV-RNA negative. Among the NAFLD patients, the frequencies of NASH and advanced stage NASH were significantly higher in male DM patients than in male patients without DM.
CONCLUSIONS: Although HBsAg- and anti-HCV Ab-positivity rates were high in our Japanese DM patients, a majority of liver injuries could be associated with NAFLD/nonalcoholic steatohepatitis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22911170     DOI: 10.1007/s00535-012-0653-5

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  19 in total

1.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis.

Authors:  Lisa Lo; Susan V McLennan; Paul F Williams; James Bonner; Sumaiya Chowdhury; Geoffrey W McCaughan; Mark D Gorrell; Dennis K Yue; Stephen M Twigg
Journal:  J Hepatol       Date:  2010-12-22       Impact factor: 25.083

Review 3.  Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity.

Authors:  L B Seeff; J H Hoofnagle
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

4.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.

Authors:  Mustafa S Ascha; Ibrahim A Hanouneh; Rocio Lopez; Tarek Abu-Rajab Tamimi; Ariel F Feldstein; Nizar N Zein
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

5.  Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale.

Authors:  Junko Tanaka; Tomiko Koyama; Masaaki Mizui; Shigeru Uchida; Keiko Katayama; Junko Matsuo; Tomoyuki Akita; Ayumu Nakashima; Yuzo Miyakawa; Hiroshi Yoshizawa
Journal:  Intervirology       Date:  2011-03-30       Impact factor: 1.763

6.  Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.

Authors:  Tania M Welzel; Barry I Graubard; Stefan Zeuzem; Hashem B El-Serag; Jessica A Davila; Katherine A McGlynn
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

7.  Pregnancy and chronic hepatitis B virus infection.

Authors:  Swati Sinha; Manoj Kumar
Journal:  Hepatol Res       Date:  2010-01       Impact factor: 4.288

8.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

9.  Etiology of liver cirrhosis in Japan: a nationwide survey.

Authors:  Kojiro Michitaka; Shuhei Nishiguchi; Yutaka Aoyagi; Yoichi Hiasa; Yoshio Tokumoto; Morikazu Onji
Journal:  J Gastroenterol       Date:  2009-09-30       Impact factor: 7.527

10.  Management of HBV infection in Japan.

Authors:  Masahito Minami; Takeshi Okanoue
Journal:  Hepatol Res       Date:  2007-07       Impact factor: 4.288

View more
  12 in total

1.  Prevalence of nonalcoholic fatty liver disease and its association with age in patients with type 2 diabetes mellitus.

Authors:  Ryosuke Yamane; Kentaro Yoshioka; Kazuhiko Hayashi; Yuko Shimizu; Yuki Ito; Komei Matsushita; Michiyo Yoshizaki; Go Kajikawa; Taro Mizutani; Atsuko Watarai; Kosuke Tachi; Hidemi Goto
Journal:  World J Hepatol       Date:  2022-06-27

2.  The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus.

Authors:  Misuzu Ueyama; Nao Nishida; Masaaki Korenaga; Keiko Korenaga; Erina Kumagai; Hidekatsu Yanai; Hiroki Adachi; Hisayuki Katsuyama; Sumie Moriyama; Hidetaka Hamasaki; Akahito Sako; Masaya Sugiyama; Yoshihiko Aoki; Masatoshi Imamura; Kazumoto Murata; Naohiko Masaki; Takumi Kawaguchi; Takuji Torimura; Hideyuki Hyogo; Hiroshi Aikata; Kiyoaki Ito; Yoshio Sumida; Akio Kanazawa; Hirotaka Watada; Koji Okamoto; Kenjiro Honda; Kazuyoshi Kon; Tatsuya Kanto; Masashi Mizokami; Sumio Watanabe
Journal:  J Gastroenterol       Date:  2015-09-03       Impact factor: 7.527

3.  Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients.

Authors:  Toshihide Shima; Hirofumi Uto; Kohjiro Ueki; Yutaka Kohgo; Kohichiroh Yasui; Naoto Nakamura; Tatsuaki Nakatou; Toshinari Takamura; Sumio Kawata; Kazuo Notsumata; Kyoko Sakai; Ryosuke Tateishi; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2018-07-13       Impact factor: 7.527

4.  Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.

Authors:  Bharat K Puchakayala; Siddharth Verma; Pushpjeet Kanwar; John Hart; Raghavendra R Sanivarapu; Smruti R Mohanty
Journal:  World J Hepatol       Date:  2015-11-08

Review 5.  Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.

Authors:  Stefano Ballestri; Fabio Nascimbeni; Dante Romagnoli; Enrica Baldelli; Giovanni Targher; Amedeo Lonardo
Journal:  Int J Mol Sci       Date:  2016-03-09       Impact factor: 5.923

6.  Clinical characteristics of patients with diabetes mellitus and fatty liver diagnosed by liver/spleen Hounsfield units on CT scan.

Authors:  Kosuke Sakitani; Kenichiro Enooku; Hirokazu Kubo; Akifumi Tanaka; Hisakatsu Arai; Shoji Kawazu; Kazuhiko Koike
Journal:  J Int Med Res       Date:  2017-05-28       Impact factor: 1.671

Review 7.  Effects of Melatonin on Liver Injuries and Diseases.

Authors:  Jiao-Jiao Zhang; Xiao Meng; Ya Li; Yue Zhou; Dong-Ping Xu; Sha Li; Hua-Bin Li
Journal:  Int J Mol Sci       Date:  2017-03-23       Impact factor: 5.923

Review 8.  Nonalcoholic fatty liver disease: Evolving paradigms.

Authors:  Amedeo Lonardo; Fabio Nascimbeni; Mauro Maurantonio; Alessandra Marrazzo; Luca Rinaldi; Luigi Elio Adinolfi
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

Review 9.  Current and future pharmacological therapies for NAFLD/NASH.

Authors:  Yoshio Sumida; Masashi Yoneda
Journal:  J Gastroenterol       Date:  2017-12-16       Impact factor: 7.527

10.  Anti-hypoglycemic and hepatocyte-protective effects of hyperoside from Zanthoxylum bungeanum leaves in mice with high-carbohydrate/high-fat diet and alloxan-induced diabetes.

Authors:  Yali Zhang; Mimi Wang; Huanhuan Dong; Xiaomin Yu; Jingfang Zhang
Journal:  Int J Mol Med       Date:  2017-10-25       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.